Grants

A list of our department's active grants and protocols; plus submitted proposals

Funded (2009-2010)


  • Nanotechnology Enabled Desktop Image-Guided Microbeam Radiation Therapy System (Grand Opportunity Grant).  Principal Investigators:  Drs. Otto Zhou and Sha Chang.  Co-investigators:  Drs. Jerry Zhang, Yanping Zhang and Eric Schreiber.  Funding Agency:  National Cancer Institute.
  • Prospective Evaluation of Cyberknife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer:  Emulating HDR Brachytherapy Dosimetry.  Principal Investigator:  Dr. David Morris.  Funding Agency:  Accuray Corporation.
  • Targeting Ras-Ral GEF-Ral Effector Signaling for Pancreatic Cancer Treatment.  Principal Investigator:  Dr. Jen Jen Yeh.  Co-investigator:  Dr. Adrienne Cox.  Funding Agency:  National Cancer Institute.
  • Retrospective Evaluation of Outcomes of PET Scanning Using the National Oncologic PET Registry.  Principal Investigator:  Dr. Michael Murray.  Co-investigator:  Dr. Ron Chen.  Funding Agency:  Agency for Healthcare Research and Quality.
  • Methodology to Exploit Calypso Transponder Coordinates and an Anatomical Shape Model for Calculating Dose to the Prostate and Proximal Rectal Wall.  Principal Investigator:  Dr. Joel Tepper.  Co-investigators:  Drs. Ed Chaney and Sha Chang.  Funding Agency:  Morphormics, Inc.
  • Pre-Clinical Validation of Pazopanib as a Lung Cancer RadiosensitizerPrincipal Investigator:  Dr. Janiel ShieldsFunding Agency:  GlaxoSmithKline, Inc.
  • In Vivo Function and Mechanism of the R-Protein-Mdm2-p53 Pathway.  Principal Investigator:  Dr. Yanping Zhang.  Funding Agency:  National Cancer Institute.
  • Nanotechnology-Enabled Compact Microbeam Radiation Therapy System for Cancer Treatment and Research.  Principal Investigators:  Drs. Otto Zhou and Sha Chang.  Funding Agency:  North Carolina Translational and Clinical Sciences Institute (NC TraCS).
  • System for Automatic Segmentation of Male Pelvis Structures.  Principal Investigator:  Dr. Sha Chang.  Co-investigators:  Drs. Ron Chen and Julian Rosenman.  Funding Agency:  Morphormics, Inc.
  • Curriculum and Modules for Computer-Based Instruction of Medical Dosimetry.  Principal Investigator:  Dr. Robert Adams.  Co-investigators:  Drs. Ed Chaney, Wally Hannum, Julian Rosenman, Eric Schreiber and Elaine Zeman, plus Mark Kostich and Gregg Tracton.  Funding Agency:  National Cancer Institute.
  • Online Collection of Patient-Specific Information for Daily Prostate Segmentation and Registration.  Principal Investigator:  Dr. Dinggang Shen.  Co-investigators:  Drs. Jun Lian, Mark Foskey, Julian Rosenman and Hongtu Zhu.  Funding Agency:  National Cancer Institute.
  • Integrating Carbon Nanotube and Micropallet Technologies for Selective Tumor Killing and Normal Tissue Sparing.  Principal Investigators:  Drs. Sha Chang, Adrienne Cox, Nancy Allbritton and Otto Zhou.  Funding Agency:  University Cancer Research Fund.
  • Retinal Oximetry:  A Novel Technology for Studying Radiation-Induced Retinopathy (RSNA Resident/Fellow Research Grant).  Principal Investigator:  Dr. Dan Higginson.  Funding Agency:  Radiological Society of North America Research and Education Foundation.
  • Improving Cancer Outcomes for African-Americans (Subcontract agreement with New Hanover Regional Medical Center, Wilmington, NC).  Principal Investigator:  Dr. Lawrence Marks.  Co-investigators:  Drs. David Morris and Joel Tepper.  Funding Agency:  National Cancer Institute.
  • Role of Downstream Signaling in EGFR/HER2 Inhibitor RadiosensitizationPrincipal Investigator:  Dr. Janiel ShieldsFunding Agency:  National Cancer Institute.
  • In Vivo Function and Mechanism of the R-Protein-Mdm2-p53 Pathway.  Principal Investigator:  Dr. Yanping Zhang.  Funding Agency:  National Cancer Institute.
  • In Vivo Function of Mdm2 E3 Ubiquitin Ligase.  Principal Investigator:  Dr. Yanping Zhang.  Funding Agency:  National Cancer Institute.
  • Radiation-Induced Cardiopulmonary Injury in Humans.  Principal Investigator:  Dr. Lawrence Marks.  Funding Agency:  National Cancer Institute.
  • CT Image Estimation for Calculation of Delivered Dose.  Principal Investigator:  Dr. Ed Chaney.  Co-investigator:  Dr. Andy Wang.  Funding Agency:  Morphormics, Inc.
  • PRINT Nanoparticles: "Calibration Quality" Nano-tools for Studying the Effect of Particle Attributes on Biodistribution, Clearance and Optimized Delivery of Therapeutics.  Principal Investigator:  Dr. Joseph DeSimone.  Co-investigators:  Drs. Jerry Zhang, Sha Chang Andy Wang and Joel Tepper.  Funding Agency:  Carolina Center of Cancer Nanotechnology Excellence (C-CCNE) /National Cancer Institute.
  • Inflammatory Biomarkers and Radiation Therapy-Induced Toxicity in Women Irradiated for Early Stage Breast Cancer.  Principal Investigator:  Dr. William Carpenter.  Co-investigators:  Drs. Lawrence Marks and Eric Schreiber.  Funding Agency:  Department of Defense.
  • Prostate Cancer Survivorship – Impact of Modern Radiation Treatment on Patient-Reported Quality of Life Outcomes.  Principal Investigator:  Dr. Ron Chen.  Funding Agency:  The Doris Duke Foundation.
  • SPORE in Gastrointestinal Cancer (Supplement).  Principal Investigator:  Dr. Joel Tepper.  Funding Agency:  National Cancer Institute.
  • Biological Activity of Ras Oncogenes.  Principal Investigator:  Dr. Channing Der.  Co-investigator:  Dr. Adrienne Cox.  Funding Agency:  National Cancer Institute.
  • Interventional Oncology: Minimally Invasive Device and Engineered Nanoparticle Neoadjuvant Therapy System for Pancreatic Cancer.  Principal Investigator:  Dr. Joseph DeSimone.  Co-investigator:  Drs. Adrienne Cox and Joel Tepper.  Funding Agency:  National Cancer Institute.
  • Epidermal Growth Factor Receptor Tyrosine Kinase Regulation of the Rho GTPase, Wrch-1.  Principal Investigator:  Dr. Adrienne Cox.  Co-investigator:  Dr. Jim Fiordalisi.  Funding Agency:  National Cancer Institute.
  • A Potential Tumor Suppressor Gene at Chromosome 17p13.3, Distal to p53, in the Pathogenesis of Lung Cancers.  Principal Investigator:  Dr. Yanping Zhang.  Funding Agency:  Department of Defense.
  • Feasibility Investigation and Development of Software Approach for a New Online Imaging System.  Principal Investigator:  Dr. Sha Chang.  Funding Agency:  Siemens Oncology Care System, USA.
  • Mitochondrial Regulation of the Mdm2-p53 Tumor Suppression Pathway.  Principal Investigator:  Dr. Yanping Zhang.  Funding Agency:  Department of Defense.
  • Smart and Rapid Retrieval of Information from Compressed Medical Image Files for Display and Diagnosis.  Principal Investigator:  Dr. Lily Tang.  Funding Agency:  Rensselaer Polytechnic Institute.
  • Development of Molecularly Targeted Nanoparticles for the Delivery of Radiosensitizers.  Principal Investigator:  Dr. Andy Wang.  Funding Agency:  Triad Golfers Against Cancer Research Grant.
  • Functional and Mechanistic Study of Mitochondrial p32, A Putative Breast Cancer Susceptibility Gene at the Chromosome 17p13.4.  Principal Investigator:  Dr. Yanping Zhang.  Funding Agency:  Department of Defense.
  • Targeted Nanoparticles for Concurrent Chemoradiation.  Principal Investigator:  Dr. Andy Wang.  Funding Agency:  Carolina Center of Cancer Nanotechnology Excellence (C-CCNE) Pilot Grant/National Cancer Institute.
  • Mechanisms of Radioresistance and Identification of Radiosensitizers in Melanoma.  Principal Investigator:  Dr. Janiel Shields.  Funding Agency:  Harry J. Lloyd Charitable Trust.
  • Paul Calabresi Career Development Award For Clinical Oncology.  Principal Investigators:  Drs. Richard Goldberg and Paul Godley.  Trainee:  Dr. Andy Wang.  Funding Agency:  National Cancer Institute.
  • Changes in Regional Retinal Oxygen Extraction and Function After Radiation Therapy.  Principal Investigators:  Dr. Bhisham Chera and Seema Garg.  Funding Agency:  North Carolina Translational and Clinical Sciences Institute (NC TraCS).
  • Neutron-Activatable Nanoparticles for Targeted Radionuclide Therapy of Tumors.  Principal Investigator:  Dr. Xiuling Lu.  Co-investigator:  Dr. Andy Wang.  Funding Agency:  North Carolina Translational and Clinical Sciences Institute (NC TraCS).

 

Submitted Proposals (2010)

 

  • Arrays for Cloning Growth Suppressed Cells.  Principal Investigator:  Dr. Nancy Allbritton.  Co-investigator:  Dr. Adrienne Cox.  Funding Agency:  National Cancer Institute.
  • Ect2 Activation and Signaling in Cytokinesis and Oncogenesis.  Principal Investigator:  Dr. Channing Der.  Co-investigator:  Dr. Adrienne Cox.  Funding Agency:  National Cancer Institute.
  • Next Generation Digital Breast Tomosynthesis Scanner.  Principal Investigator:  Dr. Otto Zhou.  Co-investigator:  Dr. Jerry Zhang.  Funding Agency:  National Cancer Institute.
  • Comparative Effectiveness of Management Options for Localized Prostate Cancer.  Principal Investigator:  Dr. Michael Murray.  Co-investigator:  Dr. Ron Chen.  Funding Agency:  Agency for Healthcare Research and Quality.
  • Mitochondrial p32 Regulation of the Mdm2-p53 Tumor Suppression Signaling and Apoptotic Cell Death.  Principal Investigator:  Dr. Yanping Zhang.  Funding Agency:  National Cancer Institute.
  • Function and Mechanism of Hep27-Mdm2-p53 Stress Response Pathway.  Principal Investigator:  Dr. Yanping Zhang.  Funding Agency:  National Cancer Institute.
  • Cancer Care Quality Research Training Program.  Principal Investigator:  Dr. Peggy Leatt.  Co-investigator:  Dr. Ron Chen.  Funding Agency:  National Cancer Institute.
  • The System of Response to DNA Damage Suppresses Environmental Melanomagenesis.  Principal Investigator:  Dr. William Kauffman.  Co-investigator:  Dr. Janiel Shields.  Funding Agency:  National Cancer Institute.
  • Stationary Tomosynthesis Instrumentation.  Principal Investigator:  Dr. Sha Chang.  Co-investigator:  Dr. Lawrence Marks.  Funding Agency:  National Cancer Institute.
  • Development of an Image-Guided, Biologically-Targeted Nanoparticle for Cancer Therapy.  Principal Investigator:  Dr. Andy Wang.  Funding Agency:  Edward Mallinckrodt, Jr. Foundation.